Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of 223Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
Bosch D, van der Velden KJM, Oving IM, Wyndaele DNJ, Weijs LE, van Schelven WD, Oyen WJG, Te Beek ET, van de Luijtgaarden ACM, Somford DM, Nagarajah J, Hermsen R, Mehra N, Gerritsen WR, van der Doelen MJ, van Oort IM. Bosch D, et al. Among authors: hermsen r. J Nucl Med. 2024 Apr 1;65(4):541-547. doi: 10.2967/jnumed.123.266654. J Nucl Med. 2024. PMID: 38423781
Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer.
de Geus-Oei LF, van der Heijden HF, Visser EP, Hermsen R, van Hoorn BA, Timmer-Bonte JN, Willemsen AT, Pruim J, Corstens FH, Krabbe PF, Oyen WJ. de Geus-Oei LF, et al. Among authors: hermsen r. J Nucl Med. 2007 Oct;48(10):1592-8. doi: 10.2967/jnumed.107.043414. Epub 2007 Sep 14. J Nucl Med. 2007. PMID: 17873138 Free article. Clinical Trial.
Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer.
de Geus-Oei LF, van Laarhoven HW, Visser EP, Hermsen R, van Hoorn BA, Kamm YJ, Krabbe PF, Corstens FH, Punt CJ, Oyen WJ. de Geus-Oei LF, et al. Among authors: hermsen r. Ann Oncol. 2008 Feb;19(2):348-52. doi: 10.1093/annonc/mdm470. Epub 2007 Oct 24. Ann Oncol. 2008. PMID: 17962202 Free article.
124I PET/CT to Predict the Outcome of Blind 131I Treatment in Patients with Biochemical Recurrence of Differentiated Thyroid Cancer: Results of a Multicenter Diagnostic Cohort Study (THYROPET).
Kist JW, de Keizer B, van der Vlies M, Brouwers AH, Huysmans DA, van der Zant FM, Hermsen R, Stokkel MP, Hoekstra OS, Vogel WV; THYROPET Study Group; other members of the THYROPET Study group are John M.H. de Klerk. Kist JW, et al. Among authors: hermsen r. J Nucl Med. 2016 May;57(5):701-7. doi: 10.2967/jnumed.115.168138. Epub 2015 Nov 25. J Nucl Med. 2016. PMID: 26609180 Free article. Clinical Trial.
Half-time bone scintigraphy in prostate and breast cancer patients.
Grootjans W, Serém SJ, Gomes MI, Heijmen L, Bulten BF, Mijnheere EP, Hermsen R, van den Broek WJ. Grootjans W, et al. Among authors: hermsen r. Q J Nucl Med Mol Imaging. 2018 Sep;62(3):303-312. doi: 10.23736/S1824-4785.16.02830-2. Epub 2016 Feb 16. Q J Nucl Med Mol Imaging. 2018. PMID: 26883516
Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Creemers JHA, van der Doelen MJ, van Wilpe S, Hermsen R, Duiveman-de Boer T, Somford DM, Janssen MJR, Sedelaar JPM, Mehra N, Textor J, Westdorp H. Creemers JHA, et al. Among authors: hermsen r. Front Oncol. 2021 May 18;11:667658. doi: 10.3389/fonc.2021.667658. eCollection 2021. Front Oncol. 2021. PMID: 34084750 Free PMC article.
Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection.
Baas DJH, Schilham M, Hermsen R, de Baaij JMS, Vrijhof HJEJ, Hoekstra RJ, Sedelaar JPM, Küsters-Vandevelde HVN, Gotthardt M, Wijers CHW, van Basten JP, Somford DM. Baas DJH, et al. Among authors: hermsen r. Prostate Cancer Prostatic Dis. 2022 Mar;25(1):65-70. doi: 10.1038/s41391-021-00452-y. Epub 2021 Sep 1. Prostate Cancer Prostatic Dis. 2022. PMID: 34471231
87 results